Abeona Therapeutics Reinitiates Enrollment in EB-101 Pivotal Phase 3 VIITAL™ Study in RDEB after COVID-19 Related Pause and Announces Progress in Patient Enrollment in MPS III Studies Jul 8, 2020
Abeona Therapeutics Announces Upcoming Data Presentations at the Society for Pediatric Dermatology 45th Annual Meeting Jun 18, 2020
Abeona Therapeutics Further Strengthens Board with Appointment of Two New Independent Directors Jun 17, 2020
Abeona Therapeutics Appoints Brian Pereira and Shawn Tomasello to the Board of Directors Apr 21, 2020
Abeona Therapeutics Announces First Patient Treated in Pivotal Phase III Clinical Trial Evaluating EB-101 Gene Therapy for Recessive Dystrophic Epidermolysis Bullosa Mar 17, 2020
Abeona Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Business Updates Mar 16, 2020
